Nexalin Technology announced it has acquired PONM from GreenLight Ventures in a $1.3 million stock transaction designed to strengthen the digital infrastructure behind Nexalin’s HALO Clarity neurostimulation platform and Nexalin NeuroCarevirtual clinic.
The acquisition gives Nexalin ownership of PONM’s AI-integrated digital health platform, including remote patient monitoring, treatment-compliance tracking, clinical-data capture, electronic health record functionality, virtual-clinic management and analytics capabilities. The technology is already deployed at University of California, San Diego, where it supports HALOheadset usage tracking, remote prescribing, physician oversight and clinical research workflows.
Nexalin said the acquisition provides greater control over the digital infrastructure connecting patients, physicians, devices and clinical workflows as the company prepares for its planned FDA pivotal trial of HALOClarity for moderate-to-severe insomnia. Enrollment for the planned 160-participant study is expected to begin in Q2 2026.
According to the company, phases one through five of the Nexalin NeuroCarevirtual clinic have already been deployed at UCSD to support patient recruitment, AI-integrated monitoring and clinical-data workflows tied to Nexalin’s traumatic brain injury and PTSD military study.
As part of the transaction, GreenLight Ventures became an equity holder in Nexalin and entered into a strategic partnership with the company. Under the agreement, Nexalin will continue to access GreenLight’s product development, engineering, quality assurance, cybersecurity, regulatory and commercial-development expertise.
The acquisition consideration will be paid in shares of Nexalin common stock issued in tranches over time based on Nexalin’s market performance.
Nexalin said it believes the transaction strengthens its strategy to integrate neurostimulation devices, AI-enabled remote monitoring and clinical-data infrastructure into a unified platform supporting future physician-supervised, at-home treatment programs.
The company develops non-invasive Deep Intracranial Frequency Stimulation (DIFS™) neurostimulation technology designed to target mid-brain structures associated with mental health disorders. Nexalin’s Gen-2 SYNC 15 milliamp neurostimulation device has received approvals in China, Brazil, Oman and Israel.
KEY QUOTES:
“This acquisition gives Nexalin ownership of a critical part of the HALOClarity ecosystem: the digital platform that connects the device, the patient, the physician and the clinical-data workflow. The PONM platform is already deployed at UCSD and supports the AI-integrated remote-monitoring, clinical-data capture and virtual-clinic capabilities we believe are essential to scaling HALOClarity. By bringing this infrastructure under Nexalin ownership, we are strengthening our ability to execute through pivotal trial activities, planned FDA submission and potential commercial launch. We believe combining HALOClarity with AI-enabled data infrastructure can strengthen treatment oversight, improve protocol adherence and create a scalable foundation for future physician-supervised, at-home neurostimulation programs.
We believe the future of neurostimulation will be defined not only by the device itself, but by the software, data and physician-supervised care model around it. This transaction strengthens Nexalin’s control over that full ecosystem and expands what we believe the Company can ultimately offer to patients and providers seeking non-invasive treatment alternatives.”
Mark White, Chief Executive Officer, Nexalin Technology
“GreenLight has spent years building digital infrastructure for next-generation healthcare technologies, and HALOClarity is exactly the type of platform our work was designed to support. With this transaction, Nexalin has the exclusive rights to the platform, while GreenLight remains aligned as both a long-term partner and shareholder. Under our strategic partnership, GreenLight’s broader product, engineering, regulatory, clinical and commercial capabilities will remain available to support HALOClarity through pivotal trial execution, regulatory submission and potential commercial launch.”
Peter Gratale, Founder, GreenLight Ventures
